The Novacyt (LON:NCYT) share price continues to tumble on delays

The Novacyt (LON:NCYT) share price continues to decline after pandemic disruptions cause a six-month delay in new product launches.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

More disappointing news continues to push the Novacyt (LSE:NCYT) share price downward. This diagnostics firm has had a rough year. After nearly half its revenue stream was wiped out following the loss of a DHSC contract, the stock tumbled almost 50% in the last 12 months. Recently, management provided an update on its research & development activities that wasn’t particularly well-received by investors. As such, the decline continues with another near-5% drop since the announcement was made.

So, what exactly are investors upset about? And is this negative performance actually a buying opportunity for my portfolio? Let’s take a closer look.

A mixed bag of an R&D update

I’ve explored Novacyt before. But as a quick reminder, it’s a medical diagnostics company that specialises in pathogen testing kits. Needless to say, the pandemic created quite a favourable environment for it to thrive in. And in 2020, this stock was like a rocket ship after it became the first company to release a Covid-19 testing kit.

Unfortunately, this first-mover advantage didn’t last long. Other companies began developing their own cheaper kits. And this fierce competition likely contributed to the loss of the DHSC contract. Since then, Novacyt has been investing its capital in creating new products for the private sector.

The latest research & development update shed some light on the progress being made. And despite what the NCYT share price would indicate, there have been some encouraging advancements. Its Winterplex test for the 2021-22 flu season has been launched. And Escapeplex, for detecting four different variants of Covid-19, is also good to go. Meanwhile, the firm has co-developed a new tool called CO-Prep. This automates the process of liquid handling by lab technicians for its PROmate testing kit, reducing the risk of contamination and saving time.

However, as encouraging as this is, further disappointing news arrived surrounding its PathFLOW kits. Due to a backlog of regulatory approval applications and supply chain disruptions, Novacyt’s Covid-19 self-lateral flow tests have been delayed. And it could be another six months before they reach the market. Given that the pandemic is slowly coming to an end, the demand for these products is bound to fall. Consequently, they may no longer be as lucrative as initially anticipated. Therefore, seeing the NCYT share price fall on the news isn’t surprising to me.

The Novacyt NCYT share price has its risks

Is the falling share price a buying opportunity?

The launch of its Winterplex and Escapeplex tests is an exciting achievement that should help recover some of the lost DHSC revenue. However, as a long-term investor, I’m not tempted by this business. Currently, the vast majority of its income originates from Covid-19-related products. Given that the pandemic is already starting to wind down, it’s unclear how this business intends to thrive in a post-Covid environment. Therefore, while the stock may be poised to surge in the coming months, I’m still keeping it on my watchlist.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »